Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lung Kee Group HoldingsHKSE:00255 67 EBITDA Margin % is 7.62% as of Dec. 2025, which is 53% below its 10-year median of 16.11. GuruFocus rates HKSE:00255 with a GF Score™ of 67/100 and a GF Value™ of HK$1.24 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 3,037 Industrial Products companies, Lung Kee Group Holdings ranks better than 50.12% on this metric.
Lung Kee Group Holdings (HKSE:00255) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lung Kee Group Holdings EBITDA Margin % Related Terms
Lung Kee Group Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00255 vs CRS, ATI, MLI: EBITDA Margin % Comparison
For the Metal Fabrication subindustry, Lung Kee Group Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lung Kee Group Holdings EBITDA Margin % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Lung Kee Group Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lung Kee Group Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lung Kee Group Holdings (HKSE:00255) has a EBITDA Margin % of 7.62% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lung Kee Group Holdings and its competitors. This is 53% below median its historical median of 16.11. Over the past decade, Lung Kee Group Holdings' EBITDA Margin % has ranged from 3.92 to 21.68. According to the industry distribution chart, Lung Kee Group Holdings ranks #1515 out of 3037 companies in the Industrial Products industry, placing it in the top 49.9%.
Is Lung Kee Group Holdings' EBITDA Margin % too high?
Lung Kee Group Holdings' current EBITDA Margin % of 7.62% is 53% below median its 10-year median of 16.11. Over the past 10 years, this metric has ranged from a low of 3.92 to a high of 21.68. The Industrial Products industry median EBITDA Margin % is 9.50. Lung Kee Group Holdings' value of 7.62% is 19.8% below this industry median. Based on the distribution chart, Lung Kee Group Holdings ranks #1515 out of 3037 companies in the Industrial Products industry, which is above the industry midpoint. Overall, Lung Kee Group Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lung Kee Group Holdings' EBITDA Margin % compare to CRS and ATI?
According to the Industrial Products industry distribution chart, Lung Kee Group Holdings ranks #1515 out of 3037 companies for EBITDA Margin %. This puts Lung Kee Group Holdings in the upper half of its industry. The industry median EBITDA Margin % is 9.50. Lung Kee Group Holdings' value of 7.62% is 19.8% below this benchmark. Historically, Lung Kee Group Holdings' own EBITDA Margin % has ranged from 3.92 to 21.68 over the past decade. While the company's 10-year median is 16.11 vs. the industry median of 9.50, Lung Kee Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Industrial Products company?
The median EBITDA Margin % among Industrial Products companies is 9.50, based on 3,037 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lung Kee Group Holdings's current EBITDA Margin % of 7.62% is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lung Kee Group Holdings and its competitors. For the Industrial Products industry, the median EBITDA Margin % is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lung Kee Group Holdings's current EBITDA Margin % is 7.62%, which is 53% below median its own 10-year median of 16.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lung Kee Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lung Kee Group Holdings (HKSE:00255) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.24, compared to a current price of HK$1.50 — trading 20.6% above its estimated fair value. The current EBITDA Margin % is 7.62%, which is 53% below median its 10-year median of 16.11 and 19.8% below the Industrial Products industry median of 9.50. Lung Kee Group Holdings' overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lung Kee Group Holdings (HKSE:00255), the current EBITDA Margin % is 7.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lung Kee Group Holdings (HKSE:00255) Overvalued in 2026?
Based on GuruFocus' analysis, Lung Kee Group Holdings stock appears to be overvalued.
The current stock price of HK$1.50 is trading 20.6% above its estimated GF Value™ of HK$1.24.
GuruFocus considers Lung Kee Group Holdings to be Modestly Overvalued.
Key valuation signals for HKSE:00255:
EBITDA Margin %: 7.62% (53% below median its 10-year median of 16.11)
GF Value™: HK$1.24 vs. price of HK$1.50 (20.6% above fair value)
Industry Position: 19.8% below the Industrial Products median (#1515 of 3037)
No single metric tells the full story. See the HKSE:00255 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lung Kee Group Holdings Ltd is an investment holding company that provides corporate management services. Along with its subsidiaries, it is engaged in the manufacturing and marketing of mould bases and related products. Its product offerings include standard and custom-made mould base, mould components, tool and steel products such as plastic and steel mould, hot and cold work steel, precision plates, standard mould inserts, and other materials. The company generates a majority of its revenue from the People's Republic of China and the rest from other markets like Asia, Europe, and America.
67GF Score
Get the complete analysis for HKSE:00255
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00255 has been successfully added to your 
